OBJECTIVE: Macrophage activation syndrome (MAS) is a devastating cytokine storm syndrome complicating many inflammatory diseases and characterized by fever, pancytopenia, and systemic inflammation. It is clinically similar to hemophagocytic lymphohistiocytosis (HLH), which is caused by viral infection of a host with impaired cellular cytotoxicity. Murine models of MAS and HLH illustrate that interferon-γ (IFNγ) is the driving stimulus for hemophagocytosis and immunopathology. This study was undertaken to investigate the inflammatory contributors to a murine model of Toll-like receptor 9 (TLR-9)-induced fulminant MAS. METHODS: Wild-type, transgenic, and cytokine-inhibited mice were treated with an IL-10 receptor blocking antibody and a TLR-9 agonist, and parameters of MAS were evaluated. RESULTS: Fulminant MAS was characterized by dramatic elevations in IFNγ, IL-12, and IL-6 levels. Increased serum IFNγ levels were associated with enhanced IFNγ production within some hepatic cell populations but also with decreased numbers of IFNγ-positive cells. Surprisingly, IFNγ-knockout mice developed immunopathology and hemophagocytosis comparable to that seen in wild-type mice. However, IFNγ-knockout mice did not become anemic and had greater numbers of splenic erythroid precursors. IL-12 neutralization phenocopied disease in IFNγ-knockout mice. Interestingly, type I IFNs contributed to the severity of hypercytokinemia and weight loss, but their absence did not otherwise affect MAS manifestations. CONCLUSION: These data demonstrate that both fulminant MAS and hemophagocytosis can arise independently of IFNγ, IL-12, or type I IFNs. They also suggest that IFNγ-mediated dyserythropoiesis, not hemophagocytosis, is the dominant cause of anemia in fulminant TLR-9-induced MAS. Thus, our data establish a novel mechanism for the acute anemia of inflammation, but suggest that a variety of triggers can result in hemophagocytic disease.
OBJECTIVE:Macrophage activation syndrome (MAS) is a devastating cytokine storm syndrome complicating many inflammatory diseases and characterized by fever, pancytopenia, and systemic inflammation. It is clinically similar to hemophagocytic lymphohistiocytosis (HLH), which is caused by viral infection of a host with impaired cellular cytotoxicity. Murine models of MAS and HLH illustrate that interferon-γ (IFNγ) is the driving stimulus for hemophagocytosis and immunopathology. This study was undertaken to investigate the inflammatory contributors to a murine model of Toll-like receptor 9 (TLR-9)-induced fulminant MAS. METHODS: Wild-type, transgenic, and cytokine-inhibited mice were treated with an IL-10 receptor blocking antibody and a TLR-9 agonist, and parameters of MAS were evaluated. RESULTS: Fulminant MAS was characterized by dramatic elevations in IFNγ, IL-12, and IL-6 levels. Increased serum IFNγ levels were associated with enhanced IFNγ production within some hepatic cell populations but also with decreased numbers of IFNγ-positive cells. Surprisingly, IFNγ-knockout mice developed immunopathology and hemophagocytosis comparable to that seen in wild-type mice. However, IFNγ-knockout mice did not become anemic and had greater numbers of splenic erythroid precursors. IL-12 neutralization phenocopied disease in IFNγ-knockout mice. Interestingly, type I IFNs contributed to the severity of hypercytokinemia and weight loss, but their absence did not otherwise affect MAS manifestations. CONCLUSION: These data demonstrate that both fulminant MAS and hemophagocytosis can arise independently of IFNγ, IL-12, or type I IFNs. They also suggest that IFNγ-mediated dyserythropoiesis, not hemophagocytosis, is the dominant cause of anemia in fulminant TLR-9-induced MAS. Thus, our data establish a novel mechanism for the acute anemia of inflammation, but suggest that a variety of triggers can result in hemophagocytic disease.
Authors: Shenghua Zhou; Anna M Cerny; An Zacharia; Katherine A Fitzgerald; Evelyn A Kurt-Jones; Robert W Finberg Journal: J Virol Date: 2010-06-30 Impact factor: 5.103
Authors: Joshua D Milner; Tatyana Orekov; Jerrold M Ward; Lily Cheng; Fernando Torres-Velez; Ilkka Junttila; Guangping Sun; Mark Buller; Suzanne C Morris; Fred D Finkelman; William E Paul Journal: Blood Date: 2010-06-22 Impact factor: 22.113
Authors: Sebastiaan J Vastert; Richard van Wijk; Leila E D'Urbano; Karen M K de Vooght; Wilco de Jager; Angelo Ravelli; Silvia Magni-Manzoni; Antonella Insalaco; Elisabetta Cortis; Wouter W van Solinge; Berent J Prakken; Nico M Wulffraat; Fabrizio de Benedetti; Wietse Kuis Journal: Rheumatology (Oxford) Date: 2009-12-17 Impact factor: 7.580
Authors: Diane E Brown; Melissa W McCoy; M Carolina Pilonieta; Rebecca N Nix; Corrella S Detweiler Journal: PLoS One Date: 2010-02-26 Impact factor: 3.240
Authors: E Brisse; M Imbrechts; T Mitera; J Vandenhaute; N Berghmans; L Boon; C Wouters; R Snoeck; G Andrei; P Matthys Journal: Clin Exp Immunol Date: 2018-01-18 Impact factor: 4.330
Authors: Tolani F Olonisakin; Tomeka Suber; Shekina Gonzalez-Ferrer; Zeyu Xiong; Hernán F Peñaloza; Rick van der Geest; Yuting Xiong; David O Osei-Hwedieh; Jesús Tejero; Matthew R Rosengart; Wendy M Mars; Daria Van Tyne; Andreas Perlegas; Samuel Brashears; Daniel B Kim-Shapiro; Mark T Gladwin; Michael A Bachman; Eldad A Hod; Claudette St Croix; Yulia Y Tyurina; Valerian E Kagan; Rama K Mallampalli; Anuradha Ray; Prabir Ray; Janet S Lee Journal: J Clin Invest Date: 2021-01-04 Impact factor: 14.808
Authors: Thomas N Burn; Lehn Weaver; Julia E Rood; Niansheng Chu; Aaron Bodansky; Portia A Kreiger; Edward M Behrens Journal: Arthritis Rheumatol Date: 2019-12-15 Impact factor: 10.995
Authors: Mark Wunderlich; Courtney Stockman; Mahima Devarajan; Navin Ravishankar; Christina Sexton; Ashish R Kumar; Benjamin Mizukawa; James C Mulloy Journal: JCI Insight Date: 2016-09-22
Authors: Scott W Canna; Patrícia Costa-Reis; William E Bernal; Niansheng Chu; Kathleen E Sullivan; Michele E Paessler; Edward M Behrens Journal: Arthritis Rheumatol Date: 2014-06 Impact factor: 10.995